Business Context and Reporting Period
This Form 8-K Current Report was filed by MaxCyte, Inc. on November 30, 2022. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and compensation arrangements rather than financial performance results.
Material Changes
The material change reported is the appointment of Patrick J. Balthrop, Sr. as a Class II Director, effective November 30, 2022. He was also appointed as a member of the Nominating and Corporate Governance Committee. His term expires at the 2023 annual meeting of stockholders.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the following compensatory arrangements for the new director:
- Stock Option: Granted a nonqualified stock option to purchase 100,000 shares of common stock at an exercise price of $5.99 per share (closing price on the grant date).
- Vesting Schedule: One-third vests after 12 months; the remainder vests monthly over the following 24 months, contingent on continuous service.
- Cash Retainer: $40,000 annual retainer for director service and an additional $5,000 annual retainer for Nominating Committee membership.
Mr. Balthrop brings over three decades of healthcare experience, including former CEO roles at Luminex Corporation and Fisher Healthcare.
Investor Verification Checklist
- Verify the impact of the new director's appointment on the composition of the Nominating and Corporate Governance Committee.
- Review the vesting terms of the 100,000 share option grant to understand potential future dilution.
- Confirm the absence of related party transactions involving Mr. Balthrop as stated in the filing.
- Check subsequent filings for the company's financial performance, as this 8-K contains no operational or financial data.